This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Innovent's Phase 3 results for Efdamrofusp Alfa (IBI302) for nAMD
Ticker(s): INNOVENT, REGN, RHHBYWho's the expert?
Institution: Johns Hopkins Medicine
- Professor in Opthalmology at John Hopkins' Eye Institute
- Manages over 1,500 patients for wet AMD
- Surgical and medical retina specialist and director of an active, multidisciplinary research laboratory developing novel retinal imaging systems, lasers and long-lasting therapies and nanotechnologies to allow physicians to determine cellular markers of disease, enabling early diagnosis, improved treatment monitoring and more individualized, personalized precision medicine tailored to each patient’s needs
Interview GoalThis conversation will focus on the treatment landscape and potential use of IBI302 for patients with wet AMD.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
